Hutchmed
HCMDrugs in Pipeline
12
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
fruquintinib+sintilimab
Advanced Renal Cell Carcinoma
HMPL-306 Regimen
Acute Myeloid Leukemia
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
Metastatic Pancreatic Cancer
fruquintinib
Advanced Endometrial Cancer
HMPL-453
Advanced Intrahepatic Cholangiocarcinoma
HMPL-760 planned dose 1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
HMPL-689
Relapsed/Refractory Lymphoma
HMPL-A251
Solid Tumors, Adult
Tazemetostat
Relapsed/Refractory Follicular Lymphoma With EZH2
Surufatinib
Neuroendocrine Tumors
Fruquintinib in Combination with Sintilimab
Advanced Solid Tumor
Surufatinib in combination with Gemcitabine
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
fruquintinib+sintilimab | Phase 3 | Advanced Renal Cell Carcinoma | - | - |
HMPL-306 Regimen | Phase 3 | Acute Myeloid Leukemia | - | - |
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine | Phase 3 | Metastatic Pancreatic Cancer | - | - |
fruquintinib | Phase 3 | Advanced Endometrial Cancer | - | - |
HMPL-453 | Phase 3 | Advanced Intrahepatic Cholangiocarcinoma | - | - |
HMPL-760 planned dose 1 | Phase 2 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | - | - |
HMPL-689 | Phase 2 | Relapsed/Refractory Lymphoma | - | - |
HMPL-A251 | Phase 2 | Solid Tumors, Adult | - | - |
Tazemetostat | Phase 2 | Relapsed/Refractory Follicular Lymphoma With EZH2 | - | - |
Surufatinib | Phase 2 | Neuroendocrine Tumors | - | - |
Fruquintinib in Combination with Sintilimab | Phase 2 | Advanced Solid Tumor | - | - |
Surufatinib in combination with Gemcitabine | Phase 2 | Solid Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hutchmed's drug pipeline?→
CatalystAlert tracks 12 drug candidates in Hutchmed's (HCM) pipeline across Phase 3, Phase 2. Its lead program is fruquintinib+sintilimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hutchmed's next FDA catalyst?→
Hutchmed's (HCM) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HCM biotech catalysts?→
Add HCM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hutchmed's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.